Aprea Therapeutics Inc
APRE
NASDAQ
Biotechnology
$0.68
USD
+0.01 (+1.33%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $8.20M
Volume 14.7K
Revenue
$5,185
TTM
-99.4%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-12.31M
TTM
+11.1%
YoY
Operating Cash Flow
$-12.17M
TTM
+4.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | -79.0% | -99.5% | -98.4% | -100.0% | -100.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.6 | 1.5 | 1.6 | 1.8 | 1.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 3.5 | 3.1 | 2.6 | 3.4 | 4.0 |
Operating Income | -3.4 | -3.1 | -2.6 | -3.4 | -4.0 |
EBITDA | -3.4 | -3.1 | -2.6 | -3.4 | -4.0 |
Other Income / Expense | -0.0 | -0.0 | 0.1 | 0.0 | 0.1 |
Total Other Income / Expense | 0.1 | 0.1 | 0.2 | 0.1 | 0.4 |
Income Before Income Taxes | -3.2 | -3.0 | -2.5 | -3.3 | -3.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -3.2 | -3.0 | -2.5 | -3.3 | -3.6 |
Consolidated Net Income / Loss | -3.2 | -3.0 | -2.5 | -3.3 | -3.6 |
Net Income Attributable to Common Shareholders | -3.2 | -3.0 | -2.5 | -3.3 | -3.6 |
Basic EPS | -$0.53 | -$0.47 | -$0.32 | -$0.22 | -$0.07 |
Diluted EPS | -$0.53 | -$0.47 | -$0.32 | -$0.22 | -$0.07 |
Basic Shares Outstanding | 6.1M | 6.4M | 7.7M | 14.7M | 53.5M |
Diluted Shares Outstanding | 6.1M | 6.4M | 7.7M | 14.7M | 53.5M |